https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
These improvements correspond with moderate to large within-group effect sizes and 43-47 % of the patients experienced clinically relevant pain reductions. About half or more of patients across the three countries were categorized as responders for pain and objective function following the implementation of GLAD®. These findings indicate positive patient outcomes associated with GLAD® participation across varying health care systems from implementation of guideline-based patient education and exercise therapy for knee and h
Curtir
Comentario
Compartilhar
